Search the Newsreel

IRadimed Corp (IRMD) Cash Flow

This article provides a detailed historical cash flow statement for IRadimed Corp (IRMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures for various cash flow components from FY2013Q1 through FY2026Q1, along with year-over-year percentage changes. The report …

CALC|CalciMedica Inc|Price:0.721|Chg%:-0.039

CalciMedica Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunologic diseases by inhibiting CRAC channels. Their lead product candidate, Auxora, is in Phase IIb trials for acute pancreatitis and supporting Phase I/II studies for asparaginase-induced pancreatic toxicity. The …

CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of CalciMedica Inc.'s (CALC) shareholder structure, detailing major shareholders and institutional holdings. It lists the top individual and venture capital firms holding significant proportions of shares, along with statistics on institutional ownership over several quarters. The data includes the …

MiMedx Group, Inc Revenue Breakdown – BOATS:MDXG

MiMedx Group, Inc. (MDXG) last year generated $418.63 million in revenue, with its top-performing segment, Wound, contributing $276.33 million. The United States was the primary geographic contributor, accounting for the entire $418.63 million in revenue last year, showing an increase from $348.88 million the …

MiMedx Group Inc (MDXG) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of MiMedx Group Inc (MDXG), noting its current valuation score of 6.65 and its position within the Biotechnology & Medical Research industry. It details the company's current P/E ratio, comparing it to historical highs and lows, while also …

CalciMedica (NASDAQ: CALC) files to register 56M shares from June 2026 PIPE

CalciMedica (NASDAQ: CALC) has filed a resale registration statement (S-3) for up to 56,020,287 shares of common stock. These shares are intended for resale by selling stockholders and include shares issued in a June 23, 2026 private placement, as well as shares issuable upon …

IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026

ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on Friday, July 31, 2026. Iradimed management will host a conference call the same day …

Before market open, IRADIMED will release Q2 results July 31

IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its Q2 2026 financial results before the market opens on Friday, July 31, 2026. Management will host a conference call at 11:00 a.m. Eastern Time the same day to discuss the results and answer questions. The …

CalciMedica (NASDAQ: CALC) plans reverse split, 7.5M-share equity plan boost and warrant votes

CalciMedica (NASDAQ: CALC) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-10, an increase of 7.5 million shares to its 2023 Equity Incentive Plan, and the approval of warrant issuances related to a recent private placement. These …

MiMedx Group Inc (MDXG) Financial Health: Profitability & Balance Sheet Analysis

MiMedx Group Inc (MDXG) has a robust financial status with a score of 8.21, ranking highly in the Biotechnology & Medical Research industry. Despite this, its latest quarterly revenue decreased by 33.12% year-over-year, and net profit saw a 254.63% decrease. The report highlights undisclosed …

MDXG|MiMedx Group Inc|Price:4.200|Chg%:+0.070

MiMedx Group Inc. (MDXG) shows strong fundamentals and high growth potential, with its valuation assessed as fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is notably high, and analysts have given it a "Buy" rating with a target price of 6.60. …

Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC

The article displays the "Price to earnings forward" metric for CalciMedica, Inc. (NASDAQ: CALC) on the TradingView platform. It shows that the value is currently not available, indicating a focus on financial data for this specific company.

Vivimed Labs reports widened net loss in FY26 amid CIRP

MiMedx Group, Inc (MDXG) Investor Outlook: Exploring a 52.42% Potential Upside Amidst Biotech Innovations

MiMedx Group, Inc. (MDXG) offers a potential 52.42% upside for investors, driven by its specialization in placental tissue allografts and innovative healthcare solutions. Despite a reported revenue growth rate of -33.10%, the company boasts a strong return on equity and free cash flow. Analysts …

CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a beneficial ownership of 1,556,081 shares of CalciMedica (CALC) common stock, representing a 5.1% equity stake. This information was reported in a Schedule 13G SEC filing. Heights Capital Management acts as the investment manager …

MIMEDX will review second-quarter results in a July 29 webcast

MiMedx (Nasdaq: MDXG) announced it will release its second-quarter 2026 operating and financial results after market close on Wednesday, July 29, 2026. The company will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to discuss the results. …

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

MiMedx Group, Inc. (Nasdaq: MDXG) announced it will report its Q2 2026 operating and financial results after market close on July 29, 2026. The company's senior management will host a webcast and conference call at 4:30 p.m. Eastern Time on the same day to …

IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock

IRADIMED (IRMD) stock has gained renewed attention, with analysts suggesting an 18% undervaluation and a fair value of $118 per share, largely due to the new 3870 MRI-compatible IV pump. While the upgrade narrative points to future revenue growth and a replacement cycle, the …

ImpediMed (ASX:IPD) Posts A$7.5M Revenue—Could This Medtech Stock Be Approaching Inflection Point?

CalciMedica (CALC) price target decreased by 24.39% to 10.54

This article reports that the price target for CalciMedica (CALC) has been decreased by 24.39%, settling at $10.54. No further details were provided regarding the reasons for this adjustment.

Iradimed Corp (IRMD) Q3 2024 Earnings Report - Results, Call & Slides

Iradimed Corp (IRMD) reported its Q3 2024 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of $0.43 against a consensus of $0.41, and actual revenue of $18.33 million against an expected $18.15 million, reflecting an 11.04% year-over-year growth. The …

Archimedes Tech SPAC Partners III Co. (ARCI) discloses director Stephen N. Cannon as insider

Forge Nano to Host Groundbreaking Event for North Carolina Lithium-Ion Battery Manufacturing Facility Expansion on August 19th

Forge Nano will host a groundbreaking event on August 19th for the expansion of its lithium-ion battery manufacturing facility in Morrisville, North Carolina. This Department of Energy-backed expansion aims to strengthen the domestic supply chain for defense and aerospace batteries, establishing a secure U.S.-owned …

MDXG Forecast — Price Target — Prediction for 2027

Bodhi Tree Multimedia secures Assam government digital platform mandate

Bodhi Tree Multimedia FY26 PAT rises 62% to ₹7.95 crore

MDXG Q1 2026 Earnings: EPS Miss Widens Losses, Stock Slips on Surprise - New Analyst Coverage

Bodhi Tree FY26 PAT rises 62% to ₹7.95 crore on IP-led growth

ImpediMed (ASX:IPD) Gains as After Reporting Encouraging Sales Momentum and Pipeline Growth

Bodhi Tree Multimedia consolidated net profit declines 15.77% in the March 2026 quarter

Vivimed Labs postpones board meeting for FY26 results

MiMedx: The Hard Math Behind My Downgrade To Hold

Some May Be Optimistic About MiMedx Group's (NASDAQ:MDXG) Earnings

Mizuho cuts MiMedx stock price target on weak wound sales

Earnings call transcript: MiMedx Q1 2026 results miss forecasts, stock dips

MiMedx: Q1 Earnings Snapshot